Downregulation of serum metabolite GTA-446 as a novel potential marker for early detection of colorectal cancer

Tsuyoshi Hata, Ichiro Takemasa, Hidekazu Takahashi, Naotsugu Haraguchi, Junichi Nishimura, Taishi Hata, Tsunekazu Mizushima, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background:We previously reported that GTA-446 may be a useful biomarker for early detection of colorectal cancer. In the present study, we confirmed the clinical feasibility of GTA-446 as a screening tool for colorectal cancer with a novel measurement system developed for clinical use. We also improved sensitivity by analysing GTA-446 levels according to gender.Methods:Serum samples were collected from 225 colorectal cancer patients and 916 healthy volunteers to measure GTA-446 levels by flow injection analysis-mass spectrometry.Results:GTA-446 levels were downregulated in colorectal cancer patients compared with the healthy volunteers, and in females compared with the males in both groups. Receiver operating characteristic curve analysis revealed an optimal cut-off of 2.72 μmol l '1 in males and 1.87 μmol l '1 in females, with a large area under the curve of 0.89-0.93. The sensitivity and specificity were 90.4% and 84.9% for males, 85.2% and 80.5% for females, and 83.3% and 84.8% for all subjects, respectively.Conclusions:GTA-446 is a clinically relevant biomarker for colorectal cancer with high sensitivity when analysed by gender. Thus, GTA-446 is a promising tool for primary colorectal cancer screening to identify populations at a higher risk of colorectal cancer, with an emphasis on early detection.

Original languageEnglish
Pages (from-to)227-232
Number of pages6
JournalBritish journal of cancer
Volume117
Issue number2
DOIs
Publication statusPublished - Jul 11 2017

Fingerprint

Early Detection of Cancer
Colorectal Neoplasms
Down-Regulation
Serum
Healthy Volunteers
Biomarkers
Flow Injection Analysis
gastrointestinal tract acid-446
ROC Curve
Area Under Curve
Mass Spectrometry
Sensitivity and Specificity
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Downregulation of serum metabolite GTA-446 as a novel potential marker for early detection of colorectal cancer. / Hata, Tsuyoshi; Takemasa, Ichiro; Takahashi, Hidekazu; Haraguchi, Naotsugu; Nishimura, Junichi; Hata, Taishi; Mizushima, Tsunekazu; Doki, Yuichiro; Mori, Masaki.

In: British journal of cancer, Vol. 117, No. 2, 11.07.2017, p. 227-232.

Research output: Contribution to journalArticle

Hata, T, Takemasa, I, Takahashi, H, Haraguchi, N, Nishimura, J, Hata, T, Mizushima, T, Doki, Y & Mori, M 2017, 'Downregulation of serum metabolite GTA-446 as a novel potential marker for early detection of colorectal cancer', British journal of cancer, vol. 117, no. 2, pp. 227-232. https://doi.org/10.1038/bjc.2017.163
Hata, Tsuyoshi ; Takemasa, Ichiro ; Takahashi, Hidekazu ; Haraguchi, Naotsugu ; Nishimura, Junichi ; Hata, Taishi ; Mizushima, Tsunekazu ; Doki, Yuichiro ; Mori, Masaki. / Downregulation of serum metabolite GTA-446 as a novel potential marker for early detection of colorectal cancer. In: British journal of cancer. 2017 ; Vol. 117, No. 2. pp. 227-232.
@article{20ddcf5fbf9f40fe8aee6f519c9fa357,
title = "Downregulation of serum metabolite GTA-446 as a novel potential marker for early detection of colorectal cancer",
abstract = "Background:We previously reported that GTA-446 may be a useful biomarker for early detection of colorectal cancer. In the present study, we confirmed the clinical feasibility of GTA-446 as a screening tool for colorectal cancer with a novel measurement system developed for clinical use. We also improved sensitivity by analysing GTA-446 levels according to gender.Methods:Serum samples were collected from 225 colorectal cancer patients and 916 healthy volunteers to measure GTA-446 levels by flow injection analysis-mass spectrometry.Results:GTA-446 levels were downregulated in colorectal cancer patients compared with the healthy volunteers, and in females compared with the males in both groups. Receiver operating characteristic curve analysis revealed an optimal cut-off of 2.72 μmol l '1 in males and 1.87 μmol l '1 in females, with a large area under the curve of 0.89-0.93. The sensitivity and specificity were 90.4{\%} and 84.9{\%} for males, 85.2{\%} and 80.5{\%} for females, and 83.3{\%} and 84.8{\%} for all subjects, respectively.Conclusions:GTA-446 is a clinically relevant biomarker for colorectal cancer with high sensitivity when analysed by gender. Thus, GTA-446 is a promising tool for primary colorectal cancer screening to identify populations at a higher risk of colorectal cancer, with an emphasis on early detection.",
author = "Tsuyoshi Hata and Ichiro Takemasa and Hidekazu Takahashi and Naotsugu Haraguchi and Junichi Nishimura and Taishi Hata and Tsunekazu Mizushima and Yuichiro Doki and Masaki Mori",
year = "2017",
month = "7",
day = "11",
doi = "10.1038/bjc.2017.163",
language = "English",
volume = "117",
pages = "227--232",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Downregulation of serum metabolite GTA-446 as a novel potential marker for early detection of colorectal cancer

AU - Hata, Tsuyoshi

AU - Takemasa, Ichiro

AU - Takahashi, Hidekazu

AU - Haraguchi, Naotsugu

AU - Nishimura, Junichi

AU - Hata, Taishi

AU - Mizushima, Tsunekazu

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2017/7/11

Y1 - 2017/7/11

N2 - Background:We previously reported that GTA-446 may be a useful biomarker for early detection of colorectal cancer. In the present study, we confirmed the clinical feasibility of GTA-446 as a screening tool for colorectal cancer with a novel measurement system developed for clinical use. We also improved sensitivity by analysing GTA-446 levels according to gender.Methods:Serum samples were collected from 225 colorectal cancer patients and 916 healthy volunteers to measure GTA-446 levels by flow injection analysis-mass spectrometry.Results:GTA-446 levels were downregulated in colorectal cancer patients compared with the healthy volunteers, and in females compared with the males in both groups. Receiver operating characteristic curve analysis revealed an optimal cut-off of 2.72 μmol l '1 in males and 1.87 μmol l '1 in females, with a large area under the curve of 0.89-0.93. The sensitivity and specificity were 90.4% and 84.9% for males, 85.2% and 80.5% for females, and 83.3% and 84.8% for all subjects, respectively.Conclusions:GTA-446 is a clinically relevant biomarker for colorectal cancer with high sensitivity when analysed by gender. Thus, GTA-446 is a promising tool for primary colorectal cancer screening to identify populations at a higher risk of colorectal cancer, with an emphasis on early detection.

AB - Background:We previously reported that GTA-446 may be a useful biomarker for early detection of colorectal cancer. In the present study, we confirmed the clinical feasibility of GTA-446 as a screening tool for colorectal cancer with a novel measurement system developed for clinical use. We also improved sensitivity by analysing GTA-446 levels according to gender.Methods:Serum samples were collected from 225 colorectal cancer patients and 916 healthy volunteers to measure GTA-446 levels by flow injection analysis-mass spectrometry.Results:GTA-446 levels were downregulated in colorectal cancer patients compared with the healthy volunteers, and in females compared with the males in both groups. Receiver operating characteristic curve analysis revealed an optimal cut-off of 2.72 μmol l '1 in males and 1.87 μmol l '1 in females, with a large area under the curve of 0.89-0.93. The sensitivity and specificity were 90.4% and 84.9% for males, 85.2% and 80.5% for females, and 83.3% and 84.8% for all subjects, respectively.Conclusions:GTA-446 is a clinically relevant biomarker for colorectal cancer with high sensitivity when analysed by gender. Thus, GTA-446 is a promising tool for primary colorectal cancer screening to identify populations at a higher risk of colorectal cancer, with an emphasis on early detection.

UR - http://www.scopus.com/inward/record.url?scp=85027001301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027001301&partnerID=8YFLogxK

U2 - 10.1038/bjc.2017.163

DO - 10.1038/bjc.2017.163

M3 - Article

C2 - 28632728

AN - SCOPUS:85027001301

VL - 117

SP - 227

EP - 232

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -